Acquisition and Supply of Oncological and Immunomodulatory Medications - (SPMS 2023/491) - PC.00484.2026 for Stock Replenishment at the Local Health Unit of Viseu Dão Lafões, E.P.E., under the Public Health Procurement Catalogue Framework Agreement.

This tender concerns the acquisition and supply of oncological and immunomodulatory medications for the Local Health Unit of Viseu Dão Lafões, E.P.E. The procurement is conducted under the framework agreement of the Public Health Procurement Catalogue (SPMS 2023/491), with the specific contract reference PC.00484.2026. The primary goal is to replenish the stock of these critical medications, which are used in the treatment of cancer and immune system disorders. Oncological and immunomodulatory drugs are highly specialized and often expensive, requiring careful management and reliable supply chains. The framework agreement mechanism ensures that these medications can be procured efficiently and at potentially negotiated prices. The contracting authority is seeking a supplier capable of providing a consistent and timely supply of the specified medications, meeting all quality and regulatory requirements. This procurement is vital for ensuring that patients receiving treatment at the Viseu Dão Lafões Local Health Unit have uninterrupted access to essential oncological and immunomodulatory therapies.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 36,221.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.